Immunotargeting therapy of MSS/pMMR — advanced endometrial cancer. Literature review and presentation of clinical practice

Drug therapy for advanced endometrial cancer (EC) has remained a challenging task for practical oncology for many years. Despite the effectiveness of standard platinum chemotherapy, most patients develop resistance to the treatment and further disease progression. Chemotherapy drugs used in the 2^nd line of therapy show unsatisfactory results in terms of effectiveness. The situation has radically changed after the discovery of the role of microsatellite instability as a predictive marker of the effectiveness of immunotherapy. EC is the leading nosology in terms of the frequency of deficient mismatch repair system (dMMR) and demonstrates a high incidence of tumors with the phenomenon of high microsatellite instability (MSI-H). For such patients, the standard of treatment has become the use of immunotherapy, in monotherapy and in combination with platinum drugs. However, 70% of patients with EC show no signs of microsatellite instability in tumor tissue (MSS/pMMR), and for many years the introduction of immunotherapy into this subgroup has been associated with very low results, not exceeding the effectiveness of standard chemotherapy regimens. Only the use of a combined approach, a combination of immunotherapy and targeted therapy demonstrated an improvement in long-term treatment outcomes, disease-free survival (DFS) and overall survival (OS) in the MSS/pMMR group of endometrial cancer. In this article, we present the literature review on the effectiveness of this regimen, demonstrate the practical experience of St. Petersburg GBUZ «City Clinical Oncology Dispensary» in using a combined regimen, and also illustrate statistical data with a real clinical case effectiveness of this treatment tactic.

1. Каприн А.Д., Иванова М.С., Петров В.В. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / под ред. А. Д. Каприна. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. ISBN 978-5-85502-298-8.

2. American Cancer Society. Endometrial cancer survival rates, by stage. Available at: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html (posting date: unknown).

3. Kelley R.M., Baker W.H. Progestational agents in the treatment of carcinoma of the endometrium // N. Engl. J. Med. 1961. Vol. 264. Р. 216–222. https://doi.org/10.1056/NEJM196102022640503.

4. Miller D.S., Filiaci V.L., Mannel R.S. et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209) // J. Clin. Oncol. 2020. Vol. 38, No. 33. Р. 3841–3850. https://doi.org/10.1200/JCO.20.01076.

5. Lincoln S., Blessing J.A., Lee R.B. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study // Gynecol. Oncol. 2003. Vol. 88, No. 3. Р. 277–281. https://doi.org/10.1016/S0090-8258(02)00068-9.

6. Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of «platinum sensitivity» to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study // Gynecol. Oncol. 2013 Dec; Vol. 131, No. 3. Р. 567–573. https://doi.org/10.1016/j.ygyno.2013.09.021.

7. Hewish M., Lord C.J., Martin S.A. et al. Mismatch repair deficient colorectal cancer in the era of personalized treatment // Nat. Rev. Clin. Oncol. 2010. Vol. 7, No. 4. Р. 197–208. https://doi.org/10.1038/nrclinonc.2010.27.

8. Lorenzi M., Amonkar M., Zhang J. et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review // J. Oncol. 2020. Vol. 2020. Р. 1807929. https://doi.org/10.1155/2020/1807929.

9. Marabelle A., O’Malley D.M., Hendifar A.E. et al. Pembrolizumab in microsatellite-instability-high and mismatchrepair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial // Nat. Cancer. 2025. Vol. 6 Р. 253–258. https://doi.org/10.1038/s43018-024-00894-y

10. Ott P.A., Bang Y.J., Berton-Rigaud D. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study // J. Clin. Oncol. 2017. Aug 1; Vol. 35, No. 22. Р. 2535–2541. https://doi.org/10.1200/JCO.2017.72.5952.

11. Makker V., Taylor M.H., Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer // J. Clin. Oncol. 2020. Vol. 38, No. 26. Р. 2981–2992. https://doi.org/10.1200/JCO.19.02627.

12. Makker V. et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775 // J. Clin. Oncol. 2023. Apr. 14. https://doi.org/10.1200/JCO.22.02152. Epub ahead of print. PMID: 37058687.

13. Colombo N., Lorusso D., Herráez A.C. et al. Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE775) // Ann. Oncol. 2021. Vol. 32, Suppl. 5. S729–S730. https://doi.org/10.1016/j.annonc.2021.08.1169.

14. Marth C. et al. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, phase III trial // J. Clin. Oncol. 2025. Vol. 43. Р. 1083–1100. https://doi.org/10.1200/JCO-24-01326.